CINRYZE™ is plasma-derived C1-I NH approved for routine prevention (prophylaxis), short-term prevention or pre-procedure prevention, and acute attacks of HAE. Among adult HAE patients, 51% miss at least one day of work (mean 3.3 days), 44% students miss at least one day of school